Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q2 2014 · 10-Q
Revenue$1.43M$1.43M+29.2% vs Q2 2013 Net Income-$199.44K-$199.44KN/M vs Q2 2013 EPS, diluted—
Gross Profit$696,668+80.5% Operating Income-$199,861N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flowderived-$376,472N/M Margins · derivedGross margin48.8%+13.9 pt vs Q2 2013
Operating margin-14.0%−46.1 pt vs Q2 2013
Net margin-14.0%−11.8 pt vs Q2 2013
ended Jun 30, 2014 · filed Aug 14, 2014 · 45 d after period end